"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 5 | 1 | 6 |
| 1998 | 1 | 4 | 5 |
| 1999 | 0 | 3 | 3 |
| 2000 | 1 | 5 | 6 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 4 | 5 | 9 |
| 2004 | 2 | 5 | 7 |
| 2005 | 4 | 4 | 8 |
| 2006 | 0 | 3 | 3 |
| 2007 | 6 | 3 | 9 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 8 | 13 |
| 2010 | 6 | 5 | 11 |
| 2011 | 4 | 10 | 14 |
| 2012 | 4 | 6 | 10 |
| 2013 | 6 | 5 | 11 |
| 2014 | 3 | 10 | 13 |
| 2015 | 3 | 2 | 5 |
| 2016 | 5 | 1 | 6 |
| 2017 | 6 | 2 | 8 |
| 2018 | 4 | 3 | 7 |
| 2019 | 1 | 5 | 6 |
| 2020 | 4 | 1 | 5 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 3 | 4 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro Oncol. 2024 Dec 05; 26(12):2316-2327.
-
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Dec 02; 30(23):5445-5458.
-
Mucosal Injection of the Silicon Phthalocyanine Pc 4 in a Rabbit Model-A Pilot Study. Laryngoscope. 2025 Jan; 135(1):270-276.
-
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024 Sep; 131(5):820-831.
-
The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry. Respir Res. 2024 Jun 21; 25(1):255.
-
Nanoscale Covalent Organic Framework with Staggered Stacking of Phthalocyanines for Mitochondria-Targeted Photodynamic Therapy. J Am Chem Soc. 2024 01 10; 146(1):849-857.
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
-
Potential Dietary and Therapeutic Strategies Involving Indole-3-Carbinole in Preclinical Models of Intestinal Inflammation. Nutrients. 2023 Nov 30; 15(23).
-
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 09; 84(3):321-330.
-
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 11; 6:e2200191.